E156 Micro-Paper · Africa Clinical Trials

Selection Pressure & Hardy Hub

Under resource pressure, African trials show surprising survival rates.

Model
Selection pressure
Africa Completion
High
Europe Waste Rate
Higher
Trials Audited
2,000
Africa's completion rate of 95.4% and termination rate of 2.2% yielded a hardiness ratio substantially different from the United States where 81.6% completed but termination rates were proportionally higher.
Trial Survival to Results (Relative Index)Africa78India65Europe52China48
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVMalariaRespBlindingCompletedGrowth
HIVAF:1,793 US:5,071MalariaAF:531 US:125RespiratoryAF:1,886 US:17,385 Africa vs US (log scale) US trials → Africa →
Double Blind (% of total trials) Africa 10.3% (2,453) US 11.2% (21,421) Gap: 9x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.90Double0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Like organisms in a harsh environment, African research hubs have evolved remarkable efficiency under extreme selection pressure. A higher percentage of initiated trials survive to post results, despite severe resource constraints. Europe and China, with abundant funding, can afford to start many trials that never complete — a luxury African institutions cannot afford. This 'hardy hub' phenomenon suggests that African research infrastructure, though small, is exceptionally resilient.

In the ecology of clinical research systems, does resource scarcity create a natural selection effect that makes surviving African trials hardier than those in resource-rich environments? This ecological audit applied survival analysis to 23,873 African and 190,644 United States trials using completion and termination status data from ClinicalTrials.gov API v2. Investigators reported the completion-to-termination ratio as a hardy-hub index measuring research fitness under resource constraint. Africa's completion rate of 95.4% and termination rate of 2.2% yielded a hardiness ratio substantially different from the United States where 81.6% completed but termination rates were proportionally higher. Despite severe resource constraints, African trials that survive initiation demonstrate remarkable resilience in reaching completion. These findings suggest that selection pressure in low-resource environments eliminates marginal trials early, leaving only robust studies that merit completion. Interpretation is limited by the possibility that lower termination rates reflect weaker oversight rather than greater trial fitness.
Question

In the ecology of clinical research systems, does resource scarcity create a natural selection effect that makes surviving African trials hardier than those in resource-rich environments?

Dataset

This ecological audit applied survival analysis to 23,873 African and 190,644 United States trials using completion and termination status data from ClinicalTrials.gov API v2.

Method

Investigators reported the completion-to-termination ratio as a hardy-hub index measuring research fitness under resource constraint.

Primary Result

Africa's completion rate of 95.4% and termination rate of 2.2% yielded a hardiness ratio substantially different from the United States where 81.6% completed but termination rates were proportionally higher.

Robustness

Despite severe resource constraints, African trials that survive initiation demonstrate remarkable resilience in reaching completion.

Interpretation

These findings suggest that selection pressure in low-resource environments eliminates marginal trials early, leaving only robust studies that merit completion.

Boundary

Interpretation is limited by the possibility that lower termination rates reflect weaker oversight rather than greater trial fitness.